KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Operations (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Cash from Operations for 16 consecutive years, with 219029000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 22.73% to 219029000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 651558000.0 through Dec 2025, up 36.01% year-over-year, with the annual reading at 651558000.0 for FY2025, 36.01% up from the prior year.
  • Cash from Operations for Q4 2025 was 219029000.0 at Halozyme Therapeutics, up from 178597000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 219029000.0 in Q4 2025, with the low at 36889000.0 in Q2 2021.
  • Average Cash from Operations over 5 years is 102937150.0, with a median of 93337500.0 recorded in 2023.
  • The sharpest move saw Cash from Operations soared 1900.97% in 2021, then plummeted 42.8% in 2022.
  • Over 5 years, Cash from Operations stood at 82516000.0 in 2021, then dropped by 0.08% to 82453000.0 in 2022, then grew by 24.14% to 102354000.0 in 2023, then soared by 74.36% to 178467000.0 in 2024, then rose by 22.73% to 219029000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 219029000.0, 178597000.0, and 99711000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.